Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3

Conditions

Neoplasms 3Solitary Fibrous Tumors 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × Capsules × Clear all
NCT04336124 2022-11-28

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

TaiRx, Inc.

Phase 1 Completed
5 enrolled
Tumor-Agnostic

Neoplasms

NCT04727138 2022-05-16

3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546

Exscientia AI Limited

Phase 1 Completed
64 enrolled
Tumor-Agnostic

Neoplasms

NCT02536391 2016-11-02

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

Genentech, Inc.

Phase 1 Completed
18 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡